International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

S. Giralt, E. A. Stadtmauer, J. L. Harousseau, A. Palumbo, W. Bensinger, R. L. Comenzo, S. Kumar, N. C. Munshi, A. Dispenzieri, R. Kyle, G. Merlini, J. San Miguel, H. Ludwig, R. Hajek, S. Jagannath, J. Blade, S. Lonial, M. A. Dimopoulos, H. Einsele, B. Barlogie & 19 others K. C. Anderson, M. Gertz, M. Attal, P. Tosi, P. Sonneveld, M. Boccadoro, G. Morgan, O. Sezer, M. V. Mateos, M. Cavo, D. Joshua, I. Turesson, W. Chen, K. Shimizu, R. Powles, P. G. Richardson, R. Niesvizky, S. V. Rajkumar, B. G M Durie

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.

Original languageEnglish
Pages (from-to)1904-1912
Number of pages9
JournalLeukemia
Volume23
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Hematopoietic Stem Cell Mobilization
Multiple Myeloma
Stem Cell Transplantation
Stem Cells
Guidelines
Colony-Stimulating Factors
Drug Therapy
Blood Component Removal
Autologous Transplantation
Therapeutics
North America
JM 3100

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). / Giralt, S.; Stadtmauer, E. A.; Harousseau, J. L.; Palumbo, A.; Bensinger, W.; Comenzo, R. L.; Kumar, S.; Munshi, N. C.; Dispenzieri, A.; Kyle, R.; Merlini, G.; San Miguel, J.; Ludwig, H.; Hajek, R.; Jagannath, S.; Blade, J.; Lonial, S.; Dimopoulos, M. A.; Einsele, H.; Barlogie, B.; Anderson, K. C.; Gertz, M.; Attal, M.; Tosi, P.; Sonneveld, P.; Boccadoro, M.; Morgan, G.; Sezer, O.; Mateos, M. V.; Cavo, M.; Joshua, D.; Turesson, I.; Chen, W.; Shimizu, K.; Powles, R.; Richardson, P. G.; Niesvizky, R.; Rajkumar, S. V.; Durie, B. G M.

In: Leukemia, Vol. 23, No. 10, 2009, p. 1904-1912.

Research output: Contribution to journalArticle

Giralt, S, Stadtmauer, EA, Harousseau, JL, Palumbo, A, Bensinger, W, Comenzo, RL, Kumar, S, Munshi, NC, Dispenzieri, A, Kyle, R, Merlini, G, San Miguel, J, Ludwig, H, Hajek, R, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, MA, Einsele, H, Barlogie, B, Anderson, KC, Gertz, M, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Sezer, O, Mateos, MV, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Richardson, PG, Niesvizky, R, Rajkumar, SV & Durie, BGM 2009, 'International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)', Leukemia, vol. 23, no. 10, pp. 1904-1912. https://doi.org/10.1038/leu.2009.127
Giralt, S. ; Stadtmauer, E. A. ; Harousseau, J. L. ; Palumbo, A. ; Bensinger, W. ; Comenzo, R. L. ; Kumar, S. ; Munshi, N. C. ; Dispenzieri, A. ; Kyle, R. ; Merlini, G. ; San Miguel, J. ; Ludwig, H. ; Hajek, R. ; Jagannath, S. ; Blade, J. ; Lonial, S. ; Dimopoulos, M. A. ; Einsele, H. ; Barlogie, B. ; Anderson, K. C. ; Gertz, M. ; Attal, M. ; Tosi, P. ; Sonneveld, P. ; Boccadoro, M. ; Morgan, G. ; Sezer, O. ; Mateos, M. V. ; Cavo, M. ; Joshua, D. ; Turesson, I. ; Chen, W. ; Shimizu, K. ; Powles, R. ; Richardson, P. G. ; Niesvizky, R. ; Rajkumar, S. V. ; Durie, B. G M. / International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). In: Leukemia. 2009 ; Vol. 23, No. 10. pp. 1904-1912.
@article{d475843295e54830ae9c07426f53db77,
title = "International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)",
abstract = "Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.",
author = "S. Giralt and Stadtmauer, {E. A.} and Harousseau, {J. L.} and A. Palumbo and W. Bensinger and Comenzo, {R. L.} and S. Kumar and Munshi, {N. C.} and A. Dispenzieri and R. Kyle and G. Merlini and {San Miguel}, J. and H. Ludwig and R. Hajek and S. Jagannath and J. Blade and S. Lonial and Dimopoulos, {M. A.} and H. Einsele and B. Barlogie and Anderson, {K. C.} and M. Gertz and M. Attal and P. Tosi and P. Sonneveld and M. Boccadoro and G. Morgan and O. Sezer and Mateos, {M. V.} and M. Cavo and D. Joshua and I. Turesson and W. Chen and K. Shimizu and R. Powles and Richardson, {P. G.} and R. Niesvizky and Rajkumar, {S. V.} and Durie, {B. G M}",
year = "2009",
doi = "10.1038/leu.2009.127",
language = "English",
volume = "23",
pages = "1904--1912",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

AU - Giralt, S.

AU - Stadtmauer, E. A.

AU - Harousseau, J. L.

AU - Palumbo, A.

AU - Bensinger, W.

AU - Comenzo, R. L.

AU - Kumar, S.

AU - Munshi, N. C.

AU - Dispenzieri, A.

AU - Kyle, R.

AU - Merlini, G.

AU - San Miguel, J.

AU - Ludwig, H.

AU - Hajek, R.

AU - Jagannath, S.

AU - Blade, J.

AU - Lonial, S.

AU - Dimopoulos, M. A.

AU - Einsele, H.

AU - Barlogie, B.

AU - Anderson, K. C.

AU - Gertz, M.

AU - Attal, M.

AU - Tosi, P.

AU - Sonneveld, P.

AU - Boccadoro, M.

AU - Morgan, G.

AU - Sezer, O.

AU - Mateos, M. V.

AU - Cavo, M.

AU - Joshua, D.

AU - Turesson, I.

AU - Chen, W.

AU - Shimizu, K.

AU - Powles, R.

AU - Richardson, P. G.

AU - Niesvizky, R.

AU - Rajkumar, S. V.

AU - Durie, B. G M

PY - 2009

Y1 - 2009

N2 - Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.

AB - Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.

UR - http://www.scopus.com/inward/record.url?scp=70350091086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350091086&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.127

DO - 10.1038/leu.2009.127

M3 - Article

VL - 23

SP - 1904

EP - 1912

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -